Rituximab and rapamycin for posttransplant lymphoproliferative disease treatment: report of three cases.
Garcia
V D
VD
Fundação Faculdade Federal de Ciências Médicas and Santa Casa Hospital, Porto Alegre, Brazil.
Bonamigo-Filho
J S
JS
Neumann
J
J
Fogliatto
L
L
Gaiger
A M
AM
Garcia
C D
CD
Barros
V
V
Keitel
E
E
Bittar
A E
AE
Santos
A F
AF
Roithmann
S
S
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008232:Lymphoproliferative Disorders / Q000188:drug therapy*; D008297:Male; D011183:Postoperative Complications / Q000188:drug therapy*; D000069283:Rituximab; D020123:Sirolimus / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab; D020123:Sirolimus